Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11661455B2 · kind B2 · utility
1Cited by
4References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 6, 2017 |
| Grant date | May 30, 2023 |
| Priority date | — |
| Expiry date | Dec 20, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.